* Note: Prices are in Million (M) USD.
Description:
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $1,927 M
Debt : $0 M
EBITDA : $-3,537 M
Since Ebitda is less than 0, 0 points assigned.
This criteria used industry in which company operates:
Sector: Healthcare
Industry: Biotechnology
Based on industry, 5 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Message: Cannot calculate PE Ratio since EPS is either 0 or negative.
Using default values for calculation.
Forward PE Ratio (using default values): 20.00
Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Average Free Cash Flow: $1,918 M
Average Revenue: $4,346 M
Revenue Converted To Free Cash FLow(%): 44%
Avg Free Cash Flow Growth Per Year (Last 5 Years): 164.98%
Since Free Cash Flow (FCF) to Revenue percentage is greater than 25, 5 points assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $3,236 M
Revenue 4 Years Ago (2020-12-31): $274 M
Last 5 Years Average Revenue Growth: 216%
Since Revenue Growth is greater than 20, 5 points assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $384 M
Share Count 5 Years Ago (2020-12-31): $381 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Message: Cannot calculate payout ratio because EPS is either 0 or negative.
Using default values for calculation.
Based on default values, 1 points assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Average ROE: -133%
Since Average ROE is negative, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $28
52-Week Low: $23
Threshold Price (15% Above 52-Week Low): $27
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $13,010 M
Since Market Cap is between 10B - 100B, 2 points assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 3% exposure of Total Portfolio.
Value-Trade has assigned 20 points to above Moderna Inc (MRNA) stock.
The fair value of Moderna Inc (MRNA) stock cannot be calculated since EBITDA and EPS are either 0 or negative.
